Phase II trial of neoadjuvant docetaxel + cisplatin + fluorouracil (DCF) therapy for esophageal cancer
Phase 2
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-UMIN000028252
- Lead Sponsor
- agoya University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1) Clear T4 other than invasion of cervical / cervical gastrointestinal tract esophageal cancer 2) Distant metastasis to other than supraclavicular lymph nodes. 3) Esophagogastric junction lesion of which main lesion is located in the stomach rather than the esophagus. 4) Judged not to be eligible by the researchers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histopathological response rate
- Secondary Outcome Measures
Name Time Method Curative resection rate, response rate in preoperative therapy, histopathological complete response rate, rate of adverse events during preoperative therapy, rate of perioperative complications, rate of late complications, rate of serious adverse events, progression-free survival, and overall survival